Want to join the conversation?
John Boris from SunTrust asks about KEYTRUDA in the US. $MRK said that right now in the US about 70% of the use is still melanoma. And there is somewhere between 10-15% that is in second line lung and the rest is among the host of different uses. So the utilization in first line lung right now is very low.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?